We aimed to assess the safety and efficacy of high-dose intermittent vitamin D supplementation in adolescents. Twenty-two healthy adolescents with serum 25 hydroxy-vitamin D (25-OHD) of 12.5-50 nmol/l were randomised to receive 300 000 IU or 150 000 IU of vitamin D3, or placebo orally 6-monthly for 1 year. At 12 months, the average vitamin D levels for the 300 000 IU, 150 000 IU and placebo groups were 63.0, 41.1 and 35.8 nmol/l, respectively, (P ¼ 0.004 for difference between 300 000 IU group and placebo after adjustment for age, sex and seasonal variation). At 12 months, one participant receiving 300 000 IU was mildly deficient (25-OHD 49 nmol/l), whereas five out of six (83%) in the placebo and four out of seven participants (57%) in the 150 000 IU group remained deficient. There were no adverse events. Compliance was high. This suggests that 300 000 IU vitamin D3 orally 6-monthly may safely and effectively correct vitamin D deficiency in adolescents.
Vitamin D deficiency is common in children (Outila et al., 2001; Lehtonen-Veromaa et al., 2002; Looker et al., 2002; Cheng et al., 2003; Jones et al., 2005) . Even subclinical deficiency may affect bone acquisition (Outila et al., 2001; Lehtonen-Veromaa et al., 2002; Cheng et al., 2003) , potentially reducing peak bone mass and negatively affecting on bone health in later life. Current evidence suggests that giving vitamin D supplements to deficient children can improve bone density (Winzenberg et al., 2010 (Winzenberg et al., , 2011 . As adherence may be a factor determining the effectiveness of supplements (Winzenberg et al., 2010 (Winzenberg et al., , 2011 and adherence is negatively associated with age (Orrell-Valente et al., 2008) , identifying simple-dose regimens, particularly for adolescents, is important. The half-life of vitamin D may be as long as 2 months (Vieth, 1999) , and high doses are well tolerated, hence, intermittent high doses may be effective (Vieth, 1999) .
As regimens with dosage intervals extending beyond 2 months in adolescents have not been studied to the authors' knowledge, we performed a double-blind randomised controlled trial comparing 6-monthly oral administration of 300 000 IU vitamin D3 (6 Â 50 000 IU tablets) and 150 000 IU vitamin D3 (3 Â 50 000 IU tablets plus 3 Â placebo) with placebo (6 Â placebo). The 50 000 IU tablets (Cal D Forte) and placebo were both manufactured by API Consumer Brands (Manukau City, Auckland, New Zealand). Recruitment was carried out by invitations mailed to students aged 15-17 years attending one public and two private schools in Southern Tasmania (latitude 421S). Responders were screened for vitamin D deficiency from July to October (late winter to early spring) and included if they had mild-tomoderate deficiency (serum 25 hydroxy-vitamin D (25-OHD) 12.5-50 nmol/l), but no clinical signs of rickets, and no known severe renal impairment, malabsorption, pregnancy or lactation. For ethical reasons, students with serum 25-OHDo12.5 nmol/l were excluded and referred to their general practitioner. Interventions were given under supervision after vitamin D measurements were taken at baseline and at 6 months. We measured serum 25-OHD at baseline, 3, 6 and 12 months using the DiaSorin radioimmunoassay kit (DiaSorin Corporation, Stillwater, MN, USA). The primary outcome was serum 25-OHD at 12 months. Serum calcium was measured 2 weeks after the first dose. Body mass index was calculated (wt (kg)/height (m 2 )). We measured sun exposure by a validated questionnaire (Dwyer et al., 1996) , which assesses daily exposure during school days, weekends and on school holidays in both summer and winter with categories of less than 2, 2-3, 3-4 or more than 4 h. We combined these categories into a single variable (total sun exposure) by calculating the weighted average, weighting by the number of school days, weekends and holidays in summer and winter. T-tests and w
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-tests were used to compare means and proportions as appropriate. Random effects mixed model analysis was used to account for correlated readings within each individual over time and examine the associations between vitamin D levels and each group (placebo versus each intervention). To capture seasonal variation we fitted models in polynomial time up to fourth power as well as two interaction (product) terms, namely time by arm and time squared by arm. A P-value o0.05 (two-tailed) was considered statistically significant. Analyses were performed with STATA 10.0 (College Station, TX, USA). This is pilot data from registered clinical trial ACTRN12608000299303, approved by the Human Research Ethics Committee (Tasmania) Network.
We screened 154 adolescents (response rate 14.4%) of whom 22 met the inclusion criteria. Seven participants were allocated each to the 300 000 IU and 150 000 IU groups and eight to placebo using central automated allocation. Age, sex distribution, body mass index, baseline sun exposure and baseline serum 25-OHD were similar across the groups (Table 1) . Participants commenced the study between 25 August 2008 and 8 December 2008. Over 12 months, two participants were lost, each from the 300 000 IU and placebo groups.
At 12 months, the average 25-OHD in the 300 000 IU, 150 000 IU and placebo groups were 63.0, 41.1 and 35.8 nmol/l, respectively, (Po0.05 for difference between 300 000 IU group and both the placebo and 150 000 IU groups; difference between 150 000 IU group and placebo not significant). After adjusting for seasonal variation, age and sex (Figure 1 ), vitamin D levels in the 150 000 IU group remained similar to those in the placebo group (P ¼ 0.657, 0.65 and 0.732 at 3, 6 and 12 months, respectively), whereas those in the 300 000 IU group were consistently higher than placebo. At 3 months, no participants in the 300 000 IU group remained deficient (Figure 2) . At 12 months, only one participant in the 300 000 IU group was deficient with a borderline serum 25-OHD level (49 nmol/l), but five of six participants in the placebo and four of seven in the 150 000 IU groups were deficient. At 2 weeks, mean serum calcium was similar in the three groups (P40.05). No Figure 1 Average vitamin D levels by group over time, adjusting for seasonal variation. To adjust for seasonal variation, participants were measured on a continuous timeline starting from when the first baseline vitamin D measurement was taken and ending when the last 12-months measurement was taken. The vertical lines intersecting the curves in the figure indicate the average time at which vitamin D levels were measured at baseline, 3, 6 and 12 months. The study was carried out in the southern hemisphere, hence, spring is from September to November, summer is from December to February, autumn is from March to May and winter is from June to August. P-values were calculated at these time points comparing both intervention groups separately to placebo. The P-values on the figure are for the comparisons between the 300 000 IU group and the placebo, which were significant at 6 (P ¼ 0.027) and 12 months (P ¼ 0.004). The difference between the 150 000 IU arm and placebo arm did not achieve statistical significance at any time point. Correcting vitamin D deficiency in adolescents J Carnes et al participants developed hypercalcaemia. There were no reported adverse events. Body mass index and sun exposure were also considered as potential confounders, but were not significant and hence were omitted from the final model.
Our results show that intermittent high-dose vitamin D supplementation may be a safe and effective alternative to more frequent dosing, provided that sufficiently high doses are given. A dosage of 300 000 IU of vitamin D3 every 6 months resulted in rapid, sustained and near-complete correction of mild-to-moderate vitamin D deficiency in adolescents, but 150 000 IU was not effective. The 6-month dosage interval is a significant advantage, as it allowed each dose to be given under supervision, resulting in adherence in adolescents completing the study of 100%, and of 91% overall. In clinical practice, high adherence is still likely to be achievable, because of the intrinsic simplicity of the regimen, and because it would be feasible for treating health professionals to implement a 6-monthly reminder system. In paediatric asthma, the simpler schedule is, the greater is the likelihood of compliance (Winnick et al., 2005) . OrrellValente et al. (2008) reported that by the age of 15 years, about 75% of children with asthma had total responsibility for their medication but that adherence was negatively associated with age. This increased risk of poor adherence in adolescents could be counteracted with intermittent dosing.
This study has some limitations. We were only able to contact children once by a mail-out through their schools, resulting in a low-response rate and potentially a healthy responder bias. Although this does not affect the generalisability of our results to other populations of vitamin Ddeficient adolescents, it highlights the potential difficulty of identifying deficient individuals in any public health intervention addressing childhood vitamin D deficiency. We excluded adolescents with severe deficiency. These may require higher and/or more frequent doses and monitoring of their serum vitamin D response would be advisable. We did not collect data on some potential confounders such as sunscreen use or dietary vitamin intake. However, our randomisation process successfully distributed other potential confounders such as sex, body mass index, and sun exposure evenly, as well as serum vitamin D levels, making it unlikely that confounding affected our results. Finally, less common adverse events may not have been detectable in this small sample.
In conclusion, 300 000 IU of vitamin D 6-monthly may be a safe, effective regimen to correct mild-to-moderate vitamin D deficiency in adolescents within high-patient adherence.
